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ABSTRACT  
Ames dwarf (df/df) mice are homozygous for a spontaneous mutation in the prop1 gene 
due to which there is no development of anterior pituitary cells – somatotrophs, lactotrophs and 
thyrotrophs, leading to a deficiency of growth hormone (GH), prolactin (PRL) and thyrotropin 
(TSH). They tend to become obese as they age, but still live longer and healthier lives compared 
to their wild-type littermates, being very insulin sensitive, showing no signs of diabetes and 
cancer. These mutant mice also have high circulating levels of anti-inflammatory and anti-
diabetic adiponectin. Plasma levels of this adipokine usually decrease with an increase in 
accumulation of visceral fat (VF). We thus believe that VF in df/df mice, developed in the 
absence of GH signaling, may be functionally different from the same fat depots in normal (N) 
mice and may be beneficial, rather than detrimental, to the overall health of the animal. We 
performed surgeries involving removal of VF depots (epididymal and perirenal fat) in both 
groups of mice and hypothesize that the beneficial effects of visceral fat removal (VFR) will be 
present exclusively in N mice as VF in df/df mice contributes to enhanced insulin sensitivity by 
producing decreased levels of pro-inflammatory adipokines like TNF and IL-6. We found that 
VFR improved insulin sensitivity only in N mice but not in the df/df mice. This intervention led 
to an upregulation of certain players of the insulin signaling pathway in the skeletal muscle of N 
mice only, with no alteration in df/df mice. The subcutaneous fat of df/df mice showed a 
downregulation of these insulin signaling genes upon VFR. Compared to N mice, epididymal fat 
of df/df mice (sham-operated) had increased gene expression of some of the players involved in 
insulin signaling and a decrease in transcript levels of TNFa. Ames dwarf mice had decreased 
levels of IL-6 protein in EF and in circulation. High circulating levels of adiponectin and 
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decreased levels of IL-6 in circulation could contribute to the high insulin sensitivity observed in 
the Ames dwarf mice. Understanding the mechanisms responsible for VF having positive effects 
on insulin signaling in df/df mice would be important for future treatment of obese diabetic 
patients.  
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CHAPTER 1: INTRODUCTION 
1.1 The Ames dwarf mouse 
Discovered in one of the mouse colonies at Iowa State University, Ames dwarf (df/df) 
mice are homozygous for a spontaneous mutation in the Prophet of pituitary factor-1 (Prop1) 
gene whose product is responsible for pituitary development. Due to the loss-of-function 
mutation, the df/df mice are devoid of three anterior pituitary cell types – somatotrophs, 
lactotrophs and thyrotrophs  –  resulting in these mutants being deficient in the hormones 
secreted by these cells – growth hormone (GH), prolactin (PRL) and thyrotropin (TSH). Though 
indistinguishable from their siblings at birth, adult df/df mice are one-third the size of their 
normal (N) littermates. These mutant mice are very insulin sensitive, having low circulating 
levels of insulin and glucose. Due to GH deficiency, circulating levels of insulin-like growth 
factor 1 (IGF-1) are significantly low in the df/df mice. These mice tend to get obese as they age. 
However, they still maintain high circulating adiponectin levels. Calorie restriction (CR) is a 
dietary intervention that is known to extend longevity and increase healthspan in rodents. 
However, through a single genetic mutation, df/df mice live significantly longer and healthier 
lives compared to N mice (figure 1) [1-3]. The difference in average lifespan between df/df and 
N mice was more than 350 days for males and more than 470 days for females [1]. Protection 
from developing age-related disorders may contribute to the enhanced lifespan and healthspan of 
these mutant dwarf mice. In addition to maintaining their youthful appearance with age, Ames 
dwarf mice do not show a decline in locomotor activity that is normally seen in aging mice; old 
mutants are much more active than the younger Ames dwarf mice [4]. Also, these mutants do not 
show an age-related decline in memory [4] and are less prone to cancer [5]. Even though df/df 
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mice share some characteristics of N mice on CR, which include small body size, decreased 
body temperature and low plasma levels of glucose, insulin and IGF-1, they are not CR 
mimetics. In fact, CR further extends the lifespan of df/df mice [6]. 
 
Figure 1: Extended longevity of Ames dwarf compared to normal mice 
(Bartke A, B.-B.H., Mattison J, Kinney B, Hauck S, Wright C., Prolonged longevity of hypopituitary 
dwarf mice. Exp Gerontol, 2001. 36(1): p. 21-8) 
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1.2 Adipose tissue 
 
                       
Figure 2: Adipose tissue depots of an adult Sv129 mouse.  
A deep cervical, B  anterior subcutaneous (interscapular, subscapular, axillo-toracic, 
superficial cervical), C  visceral mediastinic, D  visceral mesenteric, E  visceral 
retroperitoneal, F  visceral perirenal, periovaric, para- metrial and perivescical, G  posterior 
subcutaneous (dorso-lumbar, inguinal and gluteal)  
(S, C., The adipose organ. Prostaglandins Leukot Essent Fatty Acids, 2005. 73(1): p. 9-15) 
 
Mammals have two distinct types of adipose tissue – white and brown. White adipose 
tissue (WAT) serves as a fat-storing organ. It secretes several biologically active peptides 
that control whole-body insulin sensitivity. WAT also functions to provide thermal insulation 
and protects other organs from mechanical damage. Fat cells (adipocytes) in brown adipose 
tissue (BAT) have a large number of mitochondria and express uncoupling protein1 (UCP1), 
which leads to heat production via mitochondrial uncoupling of oxidative phosphorylation. 
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Thus, BAT is involved in non-shivering thermogenesis [7]; but it also exhibits anti-obesity 
and anti-diabetic properties [8]. Our study focuses exclusively on the role of WAT, located in 
the visceral cavity, on insulin signaling in df/df mice.  
1.3 Visceral fat vs. subcutaneous fat 
Subcutaneous (SQ) fat refers to adipose tissue located beneath the skin. In mice, the main 
regions of accumulation of visceral fat (VF) are around the kidney – the perirenal (PR) fat 
depot – and around the gonads – epididymal fat (EF) in males. The site of vascular drainage 
from adipose tissue can affect insulin sensitivity and glucose tolerance. SQ fat blood drains 
into systemic circulation. However, due to the location of VF in the body, the liver has direct 
access to free fatty acids and pro-inflammatory adipokines, such as TNF and IL-6, released 
by these depots via portal circulation, contributing to systemic inflammation and insulin 
resistance in obese mice as well as humans [9, 10].  
The size of adipocytes also contributes to insulin sensitivity. Small adipocytes, as found 
in SQ fat, are insulin sensitive. However, VF has a greater population of larger insulin-
resistant adipocytes [11].  
There have been several studies on laboratory animals showing that surgical removal of 
visceral fat improves insulin sensitivity and glucose tolerance (as detailed below). Moreover, 
transplanting SQ fat from donor mice into the visceral cavity of recipient mice had the most 
beneficial effects on whole-body insulin sensitivity and glucose tolerance compared to other 
fat transplantation combinations [12]. These studies strengthen the idea that SQ is ‘good’ fat 
whereas VF represents ‘bad’ body fat. 
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1.4 Calorie restriction 
Calorie restriction (CR), a decrease in the intake of calories without leading to 
malnutrition, is known to prevent or reverse many diseases associated with aging, including 
obesity and diabetes. CR leads to significant increases in longevity in many species including 
mice and rats [13]. The most striking responses to CR in mammals are a decrease in insulin 
levels, an increase in insulin sensitivity [14] and a loss of fat mass [15]. Ames dwarf mice 
exhibit several characteristics shown by wild-type mice on CR. However, the mutant dwarfs 
tend to get obese as they age; but they still benefit from the effects of CR [6].  
  
1.5 Visceral fat removal 
Several groups have carried out surgical removal of VF depots in different animal 
models, as well as in humans, to address the association of VF with insulin resistance. 
Removal of epididymal and perinephric fat pads from Sprague-Dawley rats led to an 
improvement in hepatic insulin sensitivity and also a decrease in the expression of TNF in 
subcutaneous fat [16]. Another study involving monosodium glutamate-obese (MSG-Ob) rats 
showed that visceral fat (epididmal and retroperitoneal fat) removal normalized the level of 
plasma free fatty acids (FFA) and hepatic glucose production (HGP) rate. However, removal 
of subcutaneous fat resulted only in partial normalization of the plasma level of FFA but 
HGP was not significantly decreased compared to control mice [17]. This study showed that 
visceral fat has more effect on liver insulin sensitivity and FFA concentration than does 
subcutaneous fat. The natural process of aging involves an accumulation of visceral fat, 
which could be a potential causative factor for insulin resistance. Removal of visceral fat 
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from aging rats improved peripheral and hepatic insulin sensitivity [18]. Omentectomy – 
removal of the omentum and associated fat – in dogs provided further evidence that 
extracting a small amount of visceral fat can significantly improve insulin sensitivity [19].  
Benefits of VF removal in human subjects have been conflicting. Various studies have 
been undertaken to prove or disprove the addition of omentectomy to other bariatric surgery 
procedures. One pilot study has revealed that combining omentectomy and adjustable gastric 
banding could result in beneficial, long-term effects on the metabolic profile in obese patients 
[20]. However, a study by Csendes et al compared laparotomic resectional gastric bypass 
alone and in combination with omentectomy  [21]. They reported that there was no 
difference between the two groups, two years after surgery, with respect to blood sugar 
levels, serum insulin and other parameters. They concluded that omentectomy is not justified 
as part of bariatric surgery. Furthermore, another study showed that omentectomy did not 
enhance the improvement in hepatic or peripheral insulin sensitivity in obese patients who 
underwent Roux-en-Y gastric bypass surgery, and also did not improve insulin sensitivity, 
glucose effectiveness and -cell function in obese diabetic patients [22]. It was thus inferred 
that an increase in visceral fat is not a major cause of metabolic dysfunction. Hirashita et al 
compared visceral fat resection and gastric banding in obese diabetic rats [23]. They showed 
that visceral fat removal decreased the levels of glucose and insulin. This procedure also 
increased plasma adiponectin levels and decreased circulating TNF levels. However, gastric 
banding had better effects on glucose, insulin adiponectin, TNF and insulin sensitivity 
compared to visceral fat resection. This study concluded that removal of visceral fat did have 
a small effect on improving insulin sensitivity and glucose tolerance, in comparison to gastric 
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banding. Thus, combining the two procedures did not have any additional benefit on insulin 
sensitivity and glucose tolerance. Further testing has to be carried out to justify the addition 
of VF removal to current bariatric surgery procedures.  
1.6 Fat as an endocrine organ 
Previously thought to be just a passive storage organ, it is now well accepted that adipose 
tissue functions as an endocrine organ, secreting several biologically active peptides (figure 
3)  known as adipokines which include adiponectin, TNF and IL-6 [24].  
 
 
Figure 3: Various factors secreted by white adipose tissue 
(Coelho M, O.T., Fernandes R, Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci, 
2013. 9(2): p. 191-200)  
 
The expression of adiponectin decreases with an increase in obesity [25-27] while that of 
pro-inflammatory adipokines including TNF and IL-6, increases with the accumulation of 
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visceral fat [28]. Conversely, weight loss results in an increase in the plasma levels of 
adiponectin [29-31] and a decrease in circulating levels of TNFα and IL-6 [32].  
Adiponectin exhibits anti-diabetic properties, sensitizing the body to the actions of 
insulin. It enhances insulin signaling by decreasing triglyceride levels in skeletal muscle. This 
adipokine signals through the AMP-activated protein kinase (AMPK) pathway (figure 4) leading 
to increased fatty acid oxidation and glucose uptake in myocytes and a decrease in the expression 
of enzymes involved in gluconeogenesis in the liver, thus lowering blood glucose levels [33]. In 
addition to its insulin-sensitizing effects, adiponectin also has anti-inflammatory functions; it 
inhibits the expression of endothelial adhesion molecules and proliferation of vascular smooth 
muscle cells. Adiponectin also blocks the formation of foam cells and induces the production of 
anti-inflammatory IL-10 [34]. The fact that adiponectin is indeed a beneficial adipokine was 
strengthened by experiments involving the injections of this hormone into obese, insulin-resistant 
mice leading to an improvement in insulin sensitivity [35, 36].  
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Figure 4: Metabolic processes regulated by AMPK 
 (Green  activation; red  inhibition)   
(Hardie DG, H.S., Scott JW, AMP-activated protein kinase--development of the energy sensor 
concept. J Physiol, 2006. 574(Pt 1): p. 1-15) 
 
Interleukin-6 stimulates the release of CRP from the liver. TNF terminates insulin 
signal transduction by serine-phosphorylation of insulin receptor substrate-1 (IRS-1) thus 
preventing its association with the  subunit of the insulin receptor leading to insulin resistance 
[34].   
1.7 Obesity, inflammation and diabetes 
Obesity is a serious medical condition, especially prevalent in developed countries. It was 
recently reported that more than 35% adults and around 17% children and adolescents in the 
United States are obese [37].  This state of excess fat accumulation results when there is an 
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imbalance between energy intake and expenditure. An increase in the consumption of larger 
portions of unhealthy foods and a relative decrease in physical activity are the major causes 
contributing to obesity [38, 39].  
 
Figure 5: Immune cell types in adipose tissue under lean and obese conditions 
 (Feng B, Z.T., Xu H, Human adipose dynamics and metabolic health. Ann N Y Acad Sci, 2013. 1281: 
p. 160-77) 
 
The shift in the secretion of adipokines during obesity, with the release of more pro-
inflammatory adipokines such as TNF and IL-6 and a decrease in the release of anti-
inflammatory adiponectin, leads to a chronic state of low-grade systemic inflammation. Visceral 
fat in obese subjects is infiltrated with a large number of macrophages (figure 5) [40]. The 
expression of another adipokine, monocyte chemoattractant protein-1 (MCP-1), is also increased 
in obesity [41], leading to a greater recruitment of circulating monocytes. Transgenic mice 
overexpressing MCP-1 showed an increase in the influx of macrophages into adipose tissue 
while mice with a targeted disruption of the MCP-1 gene showed reduced infiltration of 
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macrophages into adipose tissue [42]. This establishes the fact that MCP-1 plays an important 
role in the recruitment of macrophages into visceral adipose depots. Monocytes that are recruited 
into adipose tissue then differentiate into mature macrophages under the action of colony 
stimulating factor 1 (CSF1), also produced by adipocytes [34]. Importantly, macrophages also 
infiltrate adipose tissue depots in non-obese conditions. However, these are of the M2 
(alternatively activated) phenotype and thus provide protection from inflammation. In the setting 
of obesity, there is a switch from M2 to M1 (classically activated) macrophages thus contributing 
to the inflammatory state [43]. Interestingly, it was shown that the switch results from the 
recruitment of circulating macrophages of the pro-inflammatory phenotype into clusters and not 
just a conversion of resident M2 cells to the M1 phenotype in adipose tissue [44].  
Diabetes, as characterized primarily by hyperglycemia, could be due to autoimmune 
destruction of the pancreatic -cells (Type 1 diabetes) or due to target organs becoming resistant 
to the actions of insulin (Type 2 diabetes) [45]. Only 5% of diabetic patients suffer from the type 
1 form of the disease, making type 2 diabetes the most common form of this disorder, which is 
now being diagnosed across all ages and in both genders. According to the American Diabetes 
Association (ADA), 25.8 million people (8.3% of the population) in the United States have 
diabetes. Type 2 diabetes is most often associated with obesity and physical inactivity. If 
untreated, this disease could lead to several medical complications including heart disease, renal 
failure, blindness and even death [45]. Insulin resistance, associated with obesity and diabetes, 
involves insulin-target organs – adipose tissue, skeletal muscle and liver – being non-responsive 
to the actions of insulin. There is a decrease in insulin-stimulated glucose uptake in fat and 
muscle cells and reduced suppression of intrinsic glucose production by the liver [46]. As stated 
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above, visceral fat accumulation leads to a state of inflammation via secretion of pro-
inflammatory cytokines such as IL-6 and TNF. Also, the high rate of lipolysis leads to 
increased portal drainage of free fatty acids into the liver. These events hamper the insulin 
signaling pathway in the target organs leading to insulin resistance [47]. The body responds to 
elevated glucose levels by increased pancreatic secretion of insulin. However, chronic 
hyperglycemia leads to a decrease in the secretion of insulin over time due to destruction of the 
-cells.  
Treating diabetes and its associated medical complications is expensive not only for 
patients but also for national healthcare systems. Patients suffering from diabetes may even need 
hospitalization for treatment of diabetes-related conditions such as heart/kidney damage, 
blindness and limb amputation, leading to increased expenses [48]. The ADA reports a 41% 
increase in costs over a five-year period – up from $174 billion in 2007 to $245 billion in 2012. 
Developing therapeutic interventions for obesity, insulin resistance and diabetes is not only 
expensive but also a time-consuming process, which pharmaceutical companies are now 
focusing on due to the increasing number of obese diabetics.  Moreover, many such drugs, 
approved by the FDA, have adverse side effects. One such example is the class of drugs known 
as thiazolidinediones (TZD), used in the treatment of type 2 diabetes. They act via peroxisome 
proliferator-activated receptor gamma (PPAR) to improve whole-body insulin sensitivity [49]. 
However, the use of these drugs have been associated with edema and heart failure [50], 
increased osteoporosis [51] and hepatotoxicity [52].  
The study carried out here throws light on the fact that visceral fat in df/df mice differs 
from the same fat depots in N mice and does not negatively affect insulin sensitivity in these 
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mutant dwarfs. Understanding the mechanisms that underlie this differential function would be 
important for development of new therapeutic strategies to treat obese diabetic patients. Such 
therapies would involve manipulating the endocrine organ to improve insulin sensitivity at the 
whole-body level; and due to the target specificity would avoid any adverse side effects.  
1.8 The insulin signaling pathway 
Insulin is a hormone released by the pancreatic  cells and is involved in regulating blood 
glucose levels. It increases glucose disposal in skeletal muscle and adipose tissue by stimulating 
the translocation of the GLUT4 glucose transporter from its intracellular location to the plasma 
membrane and blocks intrinsic hepatic glucose production (gluconeogenesis) by inhibiting the 
activity of gluconeogenic enzymes. An excess of fat (obesity) as well as loss of fat (lipoatrophy) 
can lead to insulin resistance further emphasizing the role of fat in maintaining whole-body 
insulin sensitivity [53].  
14 
 
 
Figure 6: The insulin signaling pathway 
 (Lizcano JM, A.D., The insulin signalling pathway. Curr Biol, 2002. 12(7): p. R236-8) 
 
1. The interaction of insulin with its receptor, leads to autophosphorylation at several 
tyrosine residues of the tyrosine kinase receptor.  
2. This creates docking sites for Phosphoinositide 3-kinase (PI3K) leading to its recruitment 
at the plasma membrane.   
3. PI3K then phosphorylates phosphatidylinositol (4,5) bisphosphate (PtdIns(4,5)P2) to 
PtdIns(3,4,5)P3.  
4. A downstream effector of PtdIns(3,4,5)P3 is protein kinase B (PKB), also known as Akt, 
which binds to PtdIns(3,4,5)P3 via an amino terminus pleckstrin homology domain 
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leading to membrane recruitment. Complete activation of Akt requires phosphorylation at 
two sites – Thr 308 by PDK1 and Ser 473 by mTORC2.  
5. Activated Akt then phosphorylates a range of substrates, which includes glycogen 
synthase kinase-3 (GSK3) leading to its inactivation. Glycogen synthase, which catalyzes 
the synthesis of glycogen, is the substrate for GSK3. When phosphorylated, glycogen 
synthase is inactivated. Thus, the inhibitory phosphorylation of GSK3 by Akt leads to the 
activation of glycogen synthase [54].  
6. Glucose transported 4 (GLUT4) is expressed in skeletal muscle and adipose tissue cells. 
In the absence of insulin, GLUT4 is excluded from the cell membrane and is sequestered 
in the cytoplasm. However, upon insulin stimulation, this transporter is translocated from 
the inside of the cell to the plasma membrane [55].  
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1.9 Growth hormone, insulin sensitivity and longevity 
 
Figure 7: Mutations in growth-promoting pathways extend longevity and are conserved from yeast to mammals 
 (Longo VD, F.C., Evolutionary medicine: from dwarf model systems to healthy centenarians? Science, 2003. 299(5611): p. 1342-6) 
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In yeast, worms and flies, glucose and insulin/IGF-1 – like pathways lead to growth and 
aging of these organisms. These pathways lead to a decrease in the expression of antioxidant 
enzymes and heat shock proteins, lower accumulation of energy stores and an increase in 
mortality. However, mutations that suppress or perturb these pathways lead to an increase in 
longevity (figure 7) [56]. These ‘longevity pathways’ are conserved even in mammals. A study 
conducted by Holzenberger and colleagues showed that female IGF-1 receptor knockout mice 
(heterozygous) had increased lifespan and also exhibited higher resistance to oxidative stress, a 
factor that contributes to aging, suggesting that this receptor may regulate longevity [57]. 
As stated earlier, Ames dwarf mice have no production/secretion of GH leading to 
extremely low plasma levels of IGF-1. It was shown that the liver of df/df mice show increased 
expression of IR, IRS-1 and IRS-2 at the protein level as well as increased phosphorylation states 
of the insulin receptor substrate proteins, which could contribute to the enhanced insulin 
sensitivity of these mutants [58].  
Growth hormone receptor knock out (GHRKO) mice, generated by targeted disruption of 
the GHR gene, have elevated levels of GH in circulation. However, due to the absence of 
functional receptors, these mice are characterized by GH-resistance. Thus, they have low 
circulating levels of IGF-1 [59]. The df/df and GHRKO mice exhibit increased longevity being 
very insulin sensitive and also have high plasma levels of adiponectin even with an increase in 
adiposity [3]. The liver of GHRKO mice exhibits higher expression of IR protein as well as 
increased tyrosine phosphorylation of the receptor, leading, at least in part, to the enhanced 
insulin sensitivity seen in these mice [60]. GHRKO mice are also protected from cancer [61]. It 
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is important to note that in both these mutant dwarf mice there is a disruption of GH signaling 
either due to the absence of GH (df/df mice) or due to the inability of secreted GH to signal via 
its receptor (GHRKO mice). Thus, suppression of the GH/IGF-1 (somatotropic) axis leads to 
extended longevity and insulin sensitivity in these mice.  
The GHRKO mouse was generated as an animal model for Laron syndrome which 
affects humans. Subjects with this condition exhibit hereditary dwarfism due to a mutation in the 
GHR gene. Like the mouse model, these people exhibit a dwarf phenotype with central obesity, 
have low IGF-1 and high GH levels in circulation and due to non-functional GHR, are resistant 
to the actions of GH. The Laron dwarf humans are very insulin sensitive, showing no signs of 
diabetes and cancer [59, 62, 63]. In contrast, Transgenic mice overexpressing growth hormone 
have high circulating IGF-1 levels and increased adult body size. These giant animals are 
characterized by a decreased lifespan and insulin resistance [64]. Humans with a pathological 
excess of growth hormone (acromegaly) are also insulin resistant [34, 65] and usually do not live 
long. Moreover, administering GH to Ames dwarf mice early in life leads to a decrease in their 
longevity (figure 8)  [66] and also to reduced insulin sensitivity [67].  
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Figure 8: Decreased longevity of df/df mice upon early-life GH treatment 
(Panici JA, H.J., Miller RA, Bartke A, Spong A, Masternak MM, Early life growth hormone 
treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice. 
FASEB J, 2010. 24(12): p. 5073-9) 
 
As mentioned above, df/df and GHRKO mice live significantly longer than their wild-
type controls. Calorie restriction further extends the lifespan of df/df mice. In other words, df/df 
mice live longer than N mice, but by restricting calorie intake they live even longer. This 
extension of longevity is reflected in insulin sensitivity; df/df mice are already very insulin 
sensitive compared to N mice, but have a further increase in insulin sensitivity when on CR [68]. 
However, long-living GHRKO mice do not benefit from CR in terms of longevity, and when 
subjected to CR, they do not show any further increase in insulin sensitivity. Thus, there is a 
probable link between longevity and insulin sensitivity [68].    
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Experimental animals 
Ames dwarf and control mice used in this study were developed by crossing normal 
heterozygous (df
+/-
) female with homozygous Ames dwarf male mice, thus 50% of the F1 
population were mutant. The prop1 mutation was maintained on a heterozygous background. All 
mice were maintained in temperature controlled conditions (20-20
0
C) under 12h light/12h dark 
cycles. They had free access to drinking water and standard laboratory chow diet. Ames dwarf 
mice were weaned at 41 days while N mice were weaned at the usual 21 days.  
 
2.2 Visceral fat removal (VFR) 
Only male mice were used in this study. Ames dwarf and N mice, 3-6 months old, were 
categorized into two groups (n = 9 – 10) – visceral fat removal (VFR) or sham-operated. Surgical 
procedures were performed with mice under ketamine/xylazine anesthesia. Mice were shaved 
and prepped as usual. Ibuprofen was supplied via water 2 days before the surgery and 3 days 
after. Animals in the VFR group underwent surgical excision of the major VF depots. 
Epididymal fat was removed via a blunt dissection through a vertical midline incision, ensuring 
no damage was done to any blood vessels or the epididymis. Perirenal fat was removed by two 
flank incisions. As much fat as possible was collected without disrupting blood flow or 
damaging any organs. The excised fat was weighed and snap-frozen in liquid nitrogen and stored 
at -80
0
C until further analysis. For mice in the sham-operated group, incisions were made at the 
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same positions as on VFR animals, and VF was mobilized, but not removed. Animals were 
closely monitored for recovery post-surgery. 
2.3 Fat adiponectin and serum IL-6 levels 
Animals used for analyzing the levels of adiponectin in different fat pads and IL-6 in 
serum were about a year old. After an overnight fast, df/df (n=10) and N (n=10) mice were 
anesthetized with isofluorane. Blood was collected by cardiac puncture. Mice were sacrificed by 
cervical dislocation. Different fat pads (EF, PR and SQ) were collected and snap frozen in liquid 
nitrogen. Proteins were extracted from these fat depots before storing the tissues at -80
0
C.  
 
2.4 Analysis of glucose tolerance and whole-body insulin sensitivity 
Approximately a month after surgery, mice were subjected to a glucose tolerance test 
(GTT) to determine their ability to clear blood glucose. After overnight fasting, body weights 
were determined and the tail was snipped to collect blood samples. A baseline blood glucose 
measurement (0 min) was made using a standard glucometer. The mice were then injected 
intraperitoneally with glucose (2g glucose per kg body weight) and blood glucose levels were 
measured at defined time points (15 min, 30 min, 45 min, 60 min and 120 min). A week after 
GTT, an insulin tolerance test (ITT) was administered to these animals to determine their 
sensitivity to injected insulin at the whole-body level. For this, after body weights were 
determined and baseline blood glucose (0 min) measured, nonfasted mice were administered 
insulin (1 IU insulin/kg body weight) via an intraperitoneal injection. Blood glucose levels were 
checked at specific time points (15 min, 30 min, 45 min and 60 min).  
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2.5 Insulin stimulation and tissue collection 
Three months after surgery, mice were fasted overnight and then anesthetized with 
ketamine/xylazine. Blood was collected by cardiac puncture. In each group of mice, animals 
(approximately 50%) were injected with either a high dose of insulin (10 IU insulin/kg body 
weight) or saline (control) via the inferior vena cava to stimulate insulin signaling in target 
organs. Exactly 2 minutes after injection, mice were sacrificed by cervical dislocation, and 
tissues were collected and snap-frozen in liquid nitrogen and stored at -80
0
C till further analysis. 
At the time of tissue collection, no visible regrowth of fat was seen in the animals that had 
undergone VFR  
 
2.6 RNA extraction from frozen tissue  
RNA was extracted from skeletal muscle and adipose tissues using miRNeasy mini kit 
(Qiagen). Approximately 50 mg tissue was cut on dry ice. 300ul Qiazol reagent was added to 
each tube of frozen tissue. The samples were homogenized with zirconium oxide beads (1.0 mm 
for skeletal muscle and 0.5 mm for adipose tissue) using the bullet blender ® (Next advance) 
homogenizer (Skeletal muscle: speed 10, 3 minutes; adipose tissue: speed 8, 3minutes). Each 
tube was centrifuged for a few seconds and then 400ul of Qiazol was added and mixed by gently 
inverting the tubes, which were then allowed to incubate at room temperature for 5 min. RNA 
extraction from adipose tissue involved the additional step of centrifuging the samples at 12000 x 
g for 10 min at 4
0
C, after which the upper lipid layer was excluded and only the infranatant was 
transferred to a new tube. 140ul chloroform was then added and mixed by inverting the tubes 
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followed by incubation at room temperature for 3 minutes. Phase separation was achieved by 
centrifuging the tubes at 12,000 x g for 15 minutes at 4
0
C. The aqueous phase was transferred to 
a new tube followed by ethanol-precipitation of the RNA. Each sample was then passed through 
the RNeasy Mini spin column which bound RNA. The columns were then washed with buffers 
provided in the kit. DNase digestion was performed on-column. Pure RNA was eluted using 50ul 
and 30ul nuclease-free water (provided in the kit) for skeletal muscle and adipose tissue samples 
respectively. The concentration and purity of the eluted RNA samples were determined using the 
Take3 plate and the Epoch plate reader (BioTek).  RNA samples with A260/A280 <1.9 were re-
extracted. Extracted RNA samples were stored at -80C until further use. 
 
2.7 cDNA synthesis 
Complementary DNA was synthesized from extracted RNA samples using iScript™ 
cDNA Synthesis Kit (Bio-Rad) (Skeletal muscle and epididymal fat) or EasyScript Plus™ cDNA 
Synthesis Kit (Applied Biological Materials) (Subcutaneous fat). 1 ug of RNA was used per 
reaction.  
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Table 1: cDNA synthesis using iScript™ cDNA Synthesis Kit (Bio-Rad) 
Components Volume per reaction 
5x iScript reaction mix 4 ul 
iScript reverse transcriptase 1 ul 
Nuclease-free water Volume adjusted to 20ul 
RNA template Scaled to 1ug 
Total 20 ul 
 
The following protocol was followed using the MJ Mini thermal cycler (Bio-Rad)  
Table 2: Run protocol for iScript™ cDNA Synthesis Kit (Bio-Rad) 
Temperature Duration 
25
0
C 5  min 
42
0
C 30 min 
85
0
C 5 min 
4C Forever 
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Table 3: cDNA synthesis using EasyScript Plus™ cDNA synthesis kit (Applied Biological Materials) 
Component Volume 
Total RNA Scaled to 1ug 
Random primer (10um) 1ul 
dNTP (10mM) 1ul 
5X RT buffer 4ul 
RNaseOFF ribonuclease inhibitor (40 U/ul) 0.5ul 
EasyScript Plus™ Rtase (200 U/ul) 1ul 
RNase-free H2O Volume adjusted to 20ul 
 
Table 4: Run protocol for cDNA synthesis with EasyScript Plus™ cDNA synthesis kit (Applied 
Biological Materials) 
Temperature Duration 
25
0
C 10 min 
50
0
C 50 min 
85
0
C 5 min 
4
0
C Forever 
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2.8 Quantitative real-time polymerase chain reaction (qPCR) 
Relative gene expression was analyzed by qPCR using Fast SYBR® Green Master Mix 
(Applied Biosystems) on 7900 HT fast real-time PCR system (Applied Biosystems). Each run 
had the following steps:  
1) Enzyme activation at 950C for 20 sec 
2) Denaturation at 950C for 1 sec 
3) Annealing/extension at 620C for 20sec 
Table 5: qPCR reaction mix components 
Component Volume per reaction 
Fast SYBR® Green Master Mix 5 ul 
Forward primer (10uM) 0.2 ul 
Reverse primer (10um) 0.2 ul 
cDNA 2.0 ul 
Nuclease-free water 12.6 ul 
Total 20 ul 
 
Based on the Ct values of the housekeeping gene (b-2-microglobulin), the cDNA was 
diluted with nuclease-free water. Each sample was run in two replicates. 
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Table 6: Primer sequences for qPCR 
Gene Primer sequences (Forward and reverse) 
B2M F: 5’-AAGTATACTCACGCCACCCA-3’ 
R: 5’-CAG CGC TAT GTA TCA GTC TC-3’ 
IR F: 5’-GTTCTTTCCTGCGTGCATTTCCCA-3’ 
R: 5’-ATCAGGGTGGCCAGTGTGTCTTTA-3’ 
IRS-1 F: 5’- AGCCCAAAAGCCCAGGAGAATA-3’ 
R: 5’-TTCCGAGCCAGTCTCTTCTCTA-3’ 
IRS-2 F: 5’-AGTAAACGGAGGTGGCTACA-3’ 
R: 5’-AAGCTGAGAAGTCAAGGT-3’ 
PI3K F: 5’-TAGCTGCATTGGAGCTCCTT-3’ 
R: 5’-TACGAACTGTGGGAGCAGAT-3’ 
Akt2 F: 5-GAGGACCTTCCATGTAGACT-3’ 
R: 5’-CTCAGATGTGGAAGAGTGAC-3’ 
GLUT4 F: 5’-ATTGGCATTCTGGTTGCCCA-3’ 
R: 5’-GGTTCCGGATGATGTAGAGGTA-3’ 
PPAR F: 5’-GTCAGTACTGTCGGTTTCAG-3’ 
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R: 5’-CAGATCAGCAGACTCTGGGT-3’ 
Pgc1 F: 5’-TACGCAGGTCGAACGAAACT-3’ 
R: 5’-TGCTCTTGGTGGAAGCA-3’ 
TNF F: 5’-TAGCAAACCACCAAGTGGAG-3’ 
R: 5’-AACCTGGGAGTAGACAAGGT-3’ 
IGF-1 F: 5’-CTGAGCTGGTGGATGCTCTT-3’ 
R: 5’-CACTCATCCACACCTGT-3’ 
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2.9 Protein extraction from frozen tissue 
Total proteins were extracted from skeletal muscle and adipose tissues using T-PER 
Tissue Protein Extraction Reagent (with protease and phosphatase inhibitor) (Thermo Scientific). 
Samples were homogenized in the extraction buffer using the Bullet blender homogenizer as 
mentioned earlier. After centrifugation at 12,000 x g for 15 minutes at 4
0
C, the layer below the 
fat was collected into a new tube and centrifuged again. The relatively fat-free protein extract 
was then quantified using the BCA assay (Thermo Scientific). For the quantification assay, 
protein samples were diluted 1:10 with T-per.  
2.10 Western blotting 
Criterion™ TGX™ Precast Gels (10%) and Criterion™ Cell running tank (Bio-Rad) 
were used for SDS-PAGE. A total amount of 60ug protein was loaded in each well of the gel. 
Protein samples for Western blotting were prepared in Laemmli sample buffer (final 
concentration of 1X) (Bio-Rad) and boiled for 5 min in a dry bath (MidSci). Samples were 
centrifuged for a few seconds and then loaded onto the gel. Odyssey Protein Molecular Weight 
Marker (Li-cor) was used. Tris/Glycine/SDS (TGS) Electrophoresis Buffer (Bio-Rad) was used 
as the running buffer at a final concentration of 1X. SDS-PAGE was carried out at 100V for ~2h. 
After the run, the gel sandwich was assembled: sponge – filter paper – gel – membrane (PVDF) 
– filter paper – sponge. Transfer was carried out at 80 V for 45 min in the Criterion™ Blotter 
(Bio-Rad) using chilled Tris/Glycine (TG) buffer (Bio-Rad) with 20% methanol as the transfer 
buffer (final concentration 1X). After transfer, the membrane was rinsed with PBS for 3 min and 
then blocked with 5% milk (in PBS) for 1 hour at room temperature with gentle agitation. The 
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membrane was then rinsed with PBS-T for 30 min (5 min washes), and incubated with 1
0
 
antibody at 4
0
C overnight with gentle shaking. (1
0
 antibody buffer = Odyssey blocking buffer + 
PBS-T (1:1)). After rinsing the membrane for 30 min (5 min washes), it was incubated with 2
0
 
antibody for 1 hour at room temperature (2
0
 antibody buffer = Odyssey blocking buffer + PBS-T 
(1:1) + 0.02% SDS). The membrane was then washed for 30 min (5 min washes) and was 
imaged using the Odyssey imaging system (Li-cor) with Image studio (2.1) software. All 
primary antibodies (host: rabbit) were purchased from Cell Signaling Technology: - Akt (# 
9272), -Phospho-Akt (Ser473) (# 4060) and -Phospho-Akt (Thr308) (# 4056). Anti-rabbit 
secondary antibody was purchased from Li-cor (IRDye® 800CW Goat (polyclonal) Anti-Rabbit 
IgG). The equal intensity of non-specific bands, as revealed upon staining the membrane with the 
‘reversible protein stain’ (Thermo Scientific), was used as a loading control.  
2.11 Enzyme-linked immunosorbent assay (ELISA) for adiponectin (plasma) 
Mouse adiponectin ELISA kit (Invitrogen) was used to analyze the levels of adiponectin 
in plasma. Briefly, the plasma samples were diluted with diluent provided in the kit (dilution 
factor = 20,000). 100ul of standards, samples and QC samples were loaded on to the antibody-
coated plate and incubated at 37
0
C for 1 hour. The plate was then washed 3 times with 250ul 
wash solution (1X) using the ELx50 plate washer (BioTek), and incubated at 37
0
C for 1 hour 
with secondary antibody. After washing 3 times, the detector (1X) was added to the plate which 
was then incubated at 37
0
C for another hour. The plate was washed 5 times. After adding 100ul 
substrate solution, the plate was incubated in the dark at room temperature for 20 minutes. The 
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reaction was stopped by adding 100ul of the stop solution and the plate was read at 450 nm using 
the Epoch plate reader (BioTek).  
2.12 Enzyme-linked immunosorbent assay (ELISA) for adiponectin (adipose tissue) 
Proteins were extracted and quantified from the different fat pads (epididymal, perirenal 
and subcutaneous) of df/df and N mice as mentioned above. Extracted proteins were adjusted to 
a concentration of 0.5ug/ul in a total volume of 60ul in the same extraction buffer (T-PER) and 
then diluted to a concentration of 0.0025 ug/ul using the diluent buffer (1X) from the kit to a 
final volume of 800ul. The protocol as mentioned above was then followed. 
2.13 Enzyme-linked immunosorbent assay (ELISA) for insulin (plasma) 
 Ultra sensitive mouse insulin ELISA kit (Crystal Chem) was used for the analysis of 
insulin in plasma. 95ul of sample diluent, provided in the kit, and 5ul plasma samples were 
added to the antibody coated microplate and incubated at 4
0
C for 2 hours. The wells were then 
washed 5 times with 300ul of wash buffer and then incubated with 100ul of anti-insulin enzyme 
conjugate at room temperature for 30 min. The plate was then washed 7 times with 300ul of 
wash buffer followed by incubation, in the dark, with 100ul of enzyme substrate solution at room 
temperature for 40 min. After adding 100ul of stop solution to each well, the absorbance was 
measured at 450nm and 630nm using the Epoch plate reader (BioTek).  
2.14 Bio-Plex Pro™ Assay for IL-6 levels in serum 
Interleukin-6 levels in serum of df/df and N mice were detected using the Bio-plex assay 
(Bio-Rad). In brief, the Bio-plex 200 instrument was warmed up, calibrated and validated. 50ul 
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of magnetic beads were added to the assay plate and washed 2 times with 100ul wash buffer 
using a Handheld Magnetic Washer (Bio-Rad). 50ul samples and standards were added to the 
plate which was protected from light and incubated at room temperature for 30 min on a shaker 
at 300 rpm. The plate was then washed 3 times with wash buffer, and 25ul of detection antibody 
was added, followed by incubation as before. After another wash cycle (3 times), 50ul of 
streptavidin-PE was added to the plate and incubated at room temperature on a shaker at 300 rpm 
(protected from light) for 10 min. After a final wash step (3 times) the beads were resuspended in 
125ul assay buffer by agitating on a shaker at 1100 rpm for 30 sec. The plate was then read using 
the Bio-plex 200 system and Bio-plex manager 6.0 software. 
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CHAPTER 3 RESULTS 
3.1 Body weight and visceral fat content 
 
 
Figure 9: Effect of VFR on body weight of df/df and N mice 
 
Ames dwarf mutants were one-third the size of N mice (p < 0.0001). Surgical removal of 
visceral fat led to a significant reduction in the (fasted) body weight of N mice only (p = 0.0094) 
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Figure 10:  Visceral fat content (absolute and percentage of body weight) of N and df/df mice 
 
The weight of the fat pads removed from mice in the VFR group was measured at the 
time of surgery. Ames dwarf mice had a decreased amount of absolute visceral fat (p < 0.0001). 
The relative amount of epididymal and perirenal fat (percentage of body weight) was also lower 
in df/df compared to N mice (p = 0.0067 and p = 0.0439 respectively).  
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 3.2 Whole-body insulin sensitivity 
 
 
Figure 11: Glucose tolerance test (GTT) and insulin tolerance test (ITT) 
($, * and # indicates a significant difference (P<0.05) between the measured parameters in N Sham 
and N VFR, df/df sham and df/df VFR and N Sham and df/df sham mice respectively) 
 
 As indicated by the glucose tolerance test, surgical removal of visceral fat improved 
glucose tolerance only in N mice. There was a significant difference in blood glucose between N 
mice in the sham-operated and VFR groups at the following time points: 30 min (p = 0.0436), 45 
min (p = 0.0274) and 60 min (p = 0.0249). The difference in blood glucose between N sham and 
df/df sham mice was significant only at 45 min (p = 0.0079), 60 min (p = 0.0104) and 120 min (p 
= 0.0100) time points. At time 0 min, mice in the df/df sham group had a significantly lower 
blood glucose level than mice in the df/df VFR group (p = 0.0028).  
 The insulin tolerance test revealed that mice in the df/df sham group were very insulin 
sensitive compared to N sham mice and reached statistical significance at the different time 
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points when blood glucose levels were measured: 15 min (p = 0.0381), 30 min (p = 0.0038), 45 
min (p = 0.0090) and 60 min (p = 0.0034).  The effect of VFR on insulin sensitivity in df/df mice 
was statistically significant only at the 15 min time point (p = 0.0297). There was significant 
genotype/intervention interaction for GTT and ITT as determined by repeated measures ANOVA 
test (p = 0.0310 and p = 0.0006 respectively).  
 
Figure 12: Effect of VFR on fasting blood glucose levels 
 
Ames dwarf mice had low blood glucose levels compared to N mice (p = 0.0014). Surgically 
removing visceral fat led to an increase in the blood glucose level of df/df mice (p = 0.0020) with 
no change in the controls.  
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Figure 13: Plasma insulin levels and HOMA score  
 
Ames dwarf mice had significantly low levels of insulin in circulation, relative to N mice 
(p = 0.0125), as measured by ELISA. Visceral fat removal decreased insulin levels in plasma of 
N mice only (p = 0.0233) with no change in df/df mice. As seen by the homeostatic model 
assessment (HOMA) score, Ames dwarf mice were very insulin sensitive compared to the wild-
type littermates (p = 0.0153). Also, in parallel with decreased plasma insulin levels, surgical 
removal of visceral fat depots significantly improved insulin sensitivity in the control mice (p = 
0.0306) with no change in the mutant dwarfs.  
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3.3 Effect of VFR on expression of insulin signaling genes in skeletal muscle  
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Figure 14: Differential gene expression upon VFR in skeletal muscle of N and df/df mice 
  
Surgically removing visceral fat resulted in an upregulation of several genes involved in 
the insulin signaling pathway, as determined by qPCR, in skeletal muscle of N mice only with no 
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significant changes in df/df mice. The expression of insulin receptor (IR), insulin receptor 
substrate-2 (IRS-2), phosphoinositide 3-kinase (PI3K), Akt2, GLUT4, Peroxisome proliferator-
activated receptor gamma (PPAR) and Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1) was increased at the mRNA level in skeletal muscle of normal 
mice upon VFR compared to the sham-operated group (p = 0.0054, p = 0.0046, p = 0.0032, p = 
0.0014, p = 0.0085, p = 0.0002 and p = 0.0187 respectively).  
3.4 Effect of VFR on the phosphorylation state of Akt in skeletal muscle 
 
Figure 15: Expression of total Akt protein in skeletal muscle 
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Ames dwarf mice exhibited higher expression of total Akt protein in the skeletal muscle 
compared to N mice in insulin-stimulated and unstimulated states.  
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Figure 16: Effect of VFR on phosphorylation levels of Akt in skeletal muscle 
 
No phosphorylation signal was seen in the groups treated with saline. The highest level of 
phosphorylation of Akt at S473 and T308 was observed in df/df mice that had undergone 
surgical removal of visceral fat depots. The ratio of pAkt to Akt also showed the greatest level of 
Akt activation (phosphorylation) in the df/df VFR group.  
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3.5 Effect of VFR on expression of insulin signaling genes in subcutaneous fat 
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Figure 17: Effect of VFR on gene expression in subcutaneous fat 
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VFR lead to a decrease in the expression of the following genes in the subcutaneous fat 
of df/df mice only: IR, IRS-1, PI3K, Akt2, GLUT4 and PGC1a (p = 0.0057, p = 0.0115, p = 
0.0362, p = 0.0098, p = 0.0326 and p = 0.0428 respectively). The expression of IR and IRS-1 
transcripts was higher in the df/df sham-operated group compared to the control mice in the 
sham-operated group (p = 0.0336, p = 0.0019 respectively).   
  
46 
 
3.6 Local expression of IGF-1 in different tissues of the Ames dwarf mouse 
 
Figure 18: Local expression of IGF-1 in different tissues of df/df mice 
  
 As indicated by qPCR analysis, IGF-1 was expressed at the mRNA level in skeletal 
muscle, pituitary and adipose tissue (SQ and EF) of df/df mice. The gene expression of IGF-1 
was significantly higher in the pituitary (p = 0.046) and lower in the EF (p = 0.0033) of df/df 
47 
 
mice compared to N mice in the sham-operated group. VFR caused a significant decrease in the 
expression of IGF-1 in SQ fat of df/df mice (p = 0.0087). 
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 3.7 Differential gene expression levels in epididymal fat could contribute to enhanced 
insulin sensitivity in Ames dwarf mice 
 
Figure 19: Increased expression of genes promoting insulin sensitivity in epididymal fat of Ames 
dwarf mice 
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Gene expression analysis revealed an upregulation in the expression of IR (p = 0.0209), 
IRS-1 (p = 0.0221) and PGC1a (p = 0.0033) and a decrease in the gene expression of TNF-a (p = 
0.0114) in the epididymal fat depot of df/df mice.  
 
Figure 20: Ames dwarf mice show a downregulation in the expression of TNFa transcript in 
epididymal fat 
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3.8 Adiponectin and IL-6 protein levels in the Ames dwarf mouse 
 
Figure 21: Adiponectin levels in circulation and in different fat pads 
 
The level of adiponectin in circulation was significantly higher in df/df mice compared to 
N mice (p = 0.0031), although VFR had no difference on plasma levels of this adipokine either 
group of mice. Analysis of the adiponectin levels in different fat pads of N and df/df mice (~1 
year old) revealed no differences in the different fat depots between the two groups of mice. 
However, EF and PR fat showed high levels of adiponectin compared to SQ fat depot in N mice 
(p = 0.0038 and p = 0.0139 respectively). Also, EF in df/df mice had higher expression of 
adiponectin compared to SQ fat depot of the mutant mice (p = 0.0489).   
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Figure 22: IL-6 protein levels in EF and serum 
 
Protein levels of IL-6 were significantly low in the EF depot (p = 0.0308) of df/df mice. 
Bio-plex analysis of serum from N and df/df mice revealed a much lower level of IL-6 in 
circulation in the mutant dwarfs (p = 0.0495).  
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CHAPTER 4: DISCUSSION 
Ames dwarf and GHRKO mice share similar phenotypic characteristics, such as extended 
longevity and healthspan and enhanced insulin sensitivity. The idea that fat developed in the 
absence of GH has beneficial effects was strengthened by visceral fat removal (VFR) 
experiments in GHRKO mice [69]. This intervention led to an improvement of insulin 
sensitivity in N mice with opposite effects in GHRKO mice.   
The fact that df/df mice tend to become obese as they age, yet live longer and healthier 
lives compared to their wild-type siblings being very insulin sensitive with low circulating 
insulin and glucose levels and maintaining high plasma levels of anti-inflammatory 
adiponectin and low circulating levels of pro-inflammatory adipokines like IL-6, leads us to 
believe that the VF in these mutant dwarfs has a differential function than the same fat depots 
in N mice and does not negatively affect insulin signaling in these dwarfs.  
The mice at the time of surgery were 3-6 months old. Thus, the percentage of VF removed 
(epididymal and perirenal fat depots) was lower in the df/df compared to the N mice. 
However, this percentage would be expected to increase in the mutant dwarfs with age due to 
their propensity to gain weight with age.  
Surgically removing VF depots improved glucose tolerance only in N mice as seen by 
GTT. Moreover, GTT and ITT indicated that Ames dwarf mice showed improved glucose 
tolerance and insulin sensitivity compared to the controls, which supports previous data [2].  
Although ITT did not show any significant effect on insulin sensitivity upon VFR in either 
group of mice, the HOMA score (calculated by the formula (insulin x glucose)/22.5), which 
is a measure of insulin sensitivity, with lower values corresponding to increased insulin 
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sensitivity, indicated that VFR improved insulin sensitivity only in the control mice leading 
to significantly decreased plasma insulin levels. Also, in parallel with ITT results, HOMA 
analysis indicated that df/df mice were much more insulin sensitive than the controls. The 
decrease in plasma insulin levels seen in the N VFR group was not accompanied by a change 
in glucose levels. This suggests that the decreased levels of insulin upon fat removal are 
sufficient to maintain euglycemic levels in the controls. However, in df/df mice, this surgical 
intervention led to an increase in plasma glucose concentration with no change in the level of 
secreted insulin. It is well known that skeletal muscle and adipose tissue are the major 
insulin-responsive organs. Moreover, removal of VF lead to an upregulation of GLUT4 
mRNA in skeletal muscle of N mice, but a downregulation of this glucose transporter in the 
subcutaneous fat of df/df mice. This decreased expression of GLUT4 in SQ fat and the 
absence of functionally beneficial VF (due to VFR) in the mutants could probably lead to 
decreased glucose disposal and a corresponding increase in plasma glucose.  
Analysis of gene expression in skeletal muscle revealed that VFR could have beneficial 
effects on insulin signaling only in N mice with no significant changes in gene expression in 
df/df mice. The upregulation of insulin receptor (IR), insulin receptor substrate-2 (IRS-2), 
phosphoinositide 3-kinase (PI3K), Akt 2 and GLUT4 transcript levels in the skeletal muscle 
of the control mice with visceral fat removed probably contribute to the increased insulin 
sensitivity seen in these mice.  
Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription 
factors activated by different ligands such as fatty acids and thiazolidinediones (TZDs). Once 
activated, these nuclear receptors form heterodimers with retinoid X receptors (RXRs) and 
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bind to specific peroxisome proliferator response elements (PPREs) in the enhancers of target 
genes leading to activation of transcription of these genes [70]. Although highly expressed in 
white adipose tissue, several insulin-sensitive tissues express PPAR. Skeletal muscle PPAR 
increases glucose uptake and utilization. However, optimum expression and activation of 
PPAR seem to play an important role in maintaining whole-body insulin sensitivity. 
Muscle-specific PPAR knockout mice exhibit an increase in adiposity and develop insulin 
resistance; but are still responsive to TZDs [71]. On the other hand, in skeletal muscle of 
GHRKO mice, CR (which improves insulin sensitivity) led to a decrease in the expression of 
PPAR [70]. In our study, VFR caused an increase in the expression of PPAR as well as its 
coactivator (PGC1) at the mRNA level in skeletal of mice only in the N VFR group. Thus, 
higher PPAR expression in the skeletal muscle seems to play a role in improving whole-
body insulin sensitivity as seen with this surgical intervention in the control mice. The 
decreased insulin sensitivity seen in df/df mice upon VFR is probably not mediated by 
PPARand PGC1 expression in the skeletal muscle.   
The expression and activation of Akt in skeletal muscle was checked by Western blot. 
Total Akt levels were higher in the df/df mice compared to the controls under insulin-
stimulated as well as unstimulated states. Surprisingly, Akt activation, as determined by 
phosphorylation levels at S473 and T308, was highest in animals in the df/df VFR group 
upon insulin stimulation. The ratio of Akt (phosphorylated) to total Akt also revealed highest 
activation of Akt in the insulin-stimulated df/df mice with visceral fat removed. This would 
mean that, insulin activates the pathway to a much higher degree in the df/df mice with VF 
removed compared to the other animal groups. However, VFR does not have any beneficial 
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effects on whole-body insulin sensitivity in the df/df mice. Thus, it could be possible that this 
extent of pathway activation does not contribute positively to insulin signaling in the mutant 
mice.  On the other hand, ‘hyperactivation’ of Akt could lead to disease conditions due to its 
known role in cell survival and proliferation. However, further studies would have to be 
carried out to understand the cause and consequences of Akt activation upon fat removal in 
these dwarf mice under insulin-stimulated conditions.  
The effect of VFR on SQ fat was studied by analyzing the expression of genes involved 
in insulin signaling in this fat depot. The decrease in transcript levels of IR, IRS-1, PI3K, Akt 
2 and GLUT4 in SQ fat of df/df mice in the VFR category may, in part, contribute to the loss 
of insulin sensitivity seen in these mice. Mice with adipose-specific knock out of PGC1 are 
characterized by insulin resistance when fed a high-fat diet [72],  demonstrating its role in 
maintaining insulin sensitivity. Ames dwarf mice in the VFR group showed a decrease in the 
expression of PGC1 in SQ fat. Though there was no significant change in the gene 
expression of PPAR in this fat depot of df/df VFR mice, the lower transcript levels of 
PGC1 might explain the decreased insulin sensitivity of the mice in this group. Ames dwarf 
mice in the sham-operated groups showed an increase in gene expression of IR and IRS-1 
compared to N sham operated mice, which could explain, at least in part, the enhanced 
insulin sensitivity of the mutants.  
Since hepatic IGF-1, under the action of GH, is the primary source of circulating IGF-1, 
df/df mice have very low levels of IGF-1 in circulation. However, qPCR analysis indicated 
an expression of IGF-1 in skeletal muscle, pituitary, SQ fat and EF. This locally expressed 
IGF-1 probably acts in an autocrine/paracrine manner. Also, VFR led to a decrease in IGF-1 
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transcript level in SQ fat of df/df mice, indicating cross-talk between VF and SQ fat. This 
surgical intervention did not lead to any change in the insulin sensitivity of df/df mice. Thus, 
decreased IGF-1 expression in SQ fat may not contribute to overall insulin sensitivity of 
these animals. The mechanisms underlying the interaction between the various fat depots 
would need further investigation. 
To understand the correlation between VF and increased sensitivity of the df/df mice to 
insulin, we analyzed the gene expression of players involved in the insulin signaling pathway 
in EF of df/df and N mice in the sham-operated groups. There was an increase in the mRNA 
levels of IR, IRS-1 and PGC1 in this VF depot of df/df mice only. Moreover, the expression 
of TNF at the mRNA level was significantly lower in df/df EF relative to this fat depot of N 
mice. Ames dwarf mice also had lower levels of IL-6 protein in EF as well as in circulation, 
as revealed by Bio-plex analysis of this fat pad and serum from df/df and N mice. Moreover, 
protein levels of adiponectin were higher in EF compared to SQ fat of df/df mice. As 
expected, circulating adiponectin levels were higher in df/df mice compared to N mice; 
although VFR did not have any effect on these levels. One possible explanation for the lack 
of alteration in adiponectin levels in the mice upon VFR is that the removal of EF and PR fat 
depots causes a switch in the secretion of adiponectin by intact SQ fat as a compensatory 
mechanism. All these finding indicate the contribution of EF to positive insulin signaling in 
df/df mice.  Analysis of the different fat pads from df/df and N mice, by ELISA, did not 
show any differences between the major VF depots (EF and PR fat) or SQ fat between the 
two groups of mice. Also, EF and PR fat depots had a higher expression of adiponectin 
protein compared to SQ fat in the case of N mice. Several studies support the idea that VF 
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produces adiponectin and this intra-abdominal fat determines the level of adiponectin in 
circulation [73-75]. In our study, mice used for determining adiponectin levels in fat pads 
were healthy and non-obese. Thus, fat at different sites in these mice, functions ‘normally’ 
with no dysregulation in the secretion of adiponectin. However, obesity would lead to the 
different fat pads having a differential secretory profile, with VF producing more pro-
inflammatory adipokines and decreased adiponectin.  
In summary, as expected, df/df mice exhibited increased glucose tolerance and insulin 
sensitivity compared to the wild-type siblings. Surgical removal of VF increased glucose 
tolerance and insulin sensitivity only in N mice. This surgical intervention led to an 
upregulation of genes responsible for enhancing insulin sensitivity in the skeletal muscle of 
N mice only; but led to a decreased expression of these genes in the SQ fat of df/df mice. The 
expression of total Akt, under insulin-stimulated and unstimulated conditions, was higher in 
the skeletal muscle of df/df mice compared to the controls. For as yet unidentified reasons, 
VFR led to the highest level of Akt activation in the skeletal muscle of df/df mice when 
stimulated with insulin. Even though df/df mice have very low plasma levels of IGF-1, they 
show a local expression of IGF-1 in different tissues. The increased expression of IR, IRS-1 
and PGC1 and downregulation of TNF transcript levels as well decreased IL-6 protein 
expression in the EF and in circulation and high EF and plasma levels of adiponectin in df/df 
compared to N mice contributes to the increased insulin sensitivity of these mice. Thus, 
disruption of the GH/IGF-1 axis seems to lead to a delayed rate of aging and thus an 
extension of longevity of df/df mice (figure 23). 
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Figure 23: Proposed mechanisms of extended longevity in df/df mice
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We conclude that VF developed in the absence of GH signaling has a differential 
secretory profile and altered gene expression that does not negatively affect insulin signaling 
in df/df mice and is not detrimental to the overall health of these mutants.  
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